Latest news

• Allergan’s Avycaz breaks Gram-negative pneumonia antibiotic drought

  The antibiotic is sold in Europe by Pfizer under the Zavicefta brand name and got a green light from the EMA in 2016. ... Zavicefta is already approved in Europe for HABP/VABP. One of the key roles for the new product is in the treatment of infections

• Pfizer launches antibiotic resistance surveillance website

  Meanwhile, Pfizer’s new antibiotic for multidrug resistant (MDR) infections, Zavicefta, was launched in its first European markets earlier this year after the pharma firm paid its developer AstraZeneca $1.58bn

• Pfizer launches new antibiotic Zavicefta in UK and Germany

  The European Medicines Agency (EMA) cleared Zavicefta (ceftazidime and avibactam) for the treatment of complicated Gram-negative bacterial infections requiring hospitalisation last year. ... The availability of Zavicefta is a major step forward for

• AZ slims down again with sale of antibiotics to Pfizer

  The deal includes the approved antibiotics Merrem (meropenem), Zinforo (ceftaroline fosamil) and just-licensed Zavicefta (ceftazidime/avibactam), as well as two injectable antibiotic candidates - Allergan-partnered ATM-AVI (aztreonam/avibactam) and

• AZ gets EU green light for new antibiotic Zavicefta

  EMA approves combination drug for treatment of multidrug resistant infections. AstraZeneca's new antibiotic for multidrug resistant (MDR) infections - Zavicefta - has been approved for marketing in the EU. ... The European Medicines Agency (EMA) cleared